Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

BREAKPOINT: Cabozantinib Efficacious After Treatment with First-Line Immunotherapy

2021 Year in Review - Renal-Cell Carcinoma - Renal-Cell Carcinoma

Cabozantinib is a tyrosine kinase inhibitor (TKI) that is approved for use in combination with the immune checkpoint inhibitor nivolumab in the first-line setting and as monotherapy in all patients with advanced renal-cell carcinoma (RCC).1 However, there are limited data on the effectiveness of cabozantinib after first-line treatment with immune checkpoint inhibitors either alone or in combination with TKIs.2

In a prospective, open-label, phase 2 study, once-daily cabozantinib 60 mg was evaluated in 22 patients with advanced RCC who had previously received either adjuvant or first-line therapy with an anti–PD-1/PD-L1 checkpoint inhibitor. Previous immunotherapy could be either as a single agent or in combination with another TKI or anti–CTLA-4. Progression-free survival was the primary end point. Secondary end points included overall survival, objective response rate, and safety.2

The median age of participants was 59.5 years, and 69.5% were male. Patients had received a median of 4.3 months of previous therapy with anti–PD-1/PD-L1 inhibitors.2

On average, patients received cabozantinib for 4.7 months. The objective response rate was 27.2% (all partial responses). An additional 22.7% of patients achieved stable disease. After a median follow-up of 7.2 months, the median progression-free survival was 7.2 months.2

The most common adverse events (AEs) included hand–foot syndrome, diarrhea, hypothyroidism, mucositis, and fatigue. Grade 3 AEs were reported in 22.7% of patients. Grade 3 hand–foot syndrome was reported in 4.5% of patients. AEs led to treatment discontinuation in 2 patients. Cabozantinib dose interruption was reported in 63.6% of patients and was caused by AEs in 90% of cases. The most common reasons for cabozantinib dose interruption included hand–foot syndrome (13.9%), liver dysfunction (13.9%), diarrhea (11.6%), nausea and vomiting (11.6%), and fatigue (9.3%). AEs led to dose reduction in 22.7% of cases.2

According to the study investigators, this is the first prospective phase 2 study evaluating cabozantinib safety and efficacy after treatment with an immune checkpoint inhibitor. They concluded that cabozantinib is a tolerable agent with efficacy after immunotherapy.2

References

  1. Cabometyx (cabozantinib) tablets, for oral use [prescribing information]. Exelixis; September 2021.
  2. Procopio G, Pircher C, Claps M, et al. A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: the BREAKPOINT trial (MeetUro trial 03 - EnduraCT number 2018-000582-36). J Clin Oncol. 2021;39(6_suppl):Abstract 326.
Related Items
Reduced Starting Dose of Tyrosine Kinase Inhibitors in Patients with Metastatic Renal-Cell Carcinoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Renal-Cell Carcinoma, Dose Escalation/Reduction
Renal-Cell Carcinoma Year in Review Introduction
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
KEYNOTE-564: Adjuvant Pembrolizumab Improves Outcomes in RCC
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
CLEAR: Lenvatinib plus Pembrolizumab Improves Progression-Free Survival and Overall Survival versus Sunitinib in First-Line Setting
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
CheckMate-9ER: Nivolumab plus Cabozantinib Extends Progression-Free Survival and Overall Survival Compared with Sunitinib
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
TIVO-3: Post-Hoc and Subgroup Analyses of Third- and Fourth-Line Tivozanib Treatment Compared with Sorafenib
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
KEYNOTE-146: Lenvatinib plus Pembrolizumab Tolerable and Effective in Treatment-Naïve and Previously Treated Patients with RCC
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
IMmotion150: Atezolizumab plus Bevacizumab Safe and Efficacious in Pretreated Disease
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Belzutifan Shows Promise as a Novel Option for Advanced Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
COSMIC-021: Antitumor Activity with Cabozantinib plus Atezolizumab for Clear-Cell and Non–Clear-Cell Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma published on January 20, 2022 in Renal-Cell Carcinoma
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.